2-溴-5-乙氧基苯甲酸甲酯 | 765944-34-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-溴-5-乙氧基苯甲酸甲酯
• 英文名称: 5-ethoxy-2-bromo-benzoic acid methyl ester
• 英文别名: 5-Aethoxy-2-brom-benzoesaeure-methylester；2-bromo-5-ethoxybenzoic acid methyl ester；Methyl 2-bromo-5-ethoxybenzoate；methyl 2-bromo-5-ethoxybenzoate
• CAS: 765944-34-1
• 化学式: C₁₀H₁₁BrO₃
• 分子量: 259.1
• InChiKey: NWUTUUJXNFWIAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-溴-5-乙氧基苯甲酸甲酯 在 tris-(dibenzylideneacetone)dipalladium(0) sodium hydroxide 、 氯化亚砜 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 乙醇 、 水 为溶剂， 生成 9H-Fluoren-9-one, 2,7-diethoxy-
  参考文献：
  名称：

  Chronobiotic activity of N-[2-(2,7-dimethoxyfluoren-9-yl)ethyl]-propanamide. Synthesis and melatonergic pharmacology of fluoren-9-ylethyl amides

  摘要：

  A series of fluoren-9-yl ethyl amides (2) were synthesized and evaluated for human melatonin MT1 and MT2 receptor binding. N-[2-(2,7-dimethoxyfluoren-9-yl)ethyl]propanamide (2b) was selected and evaluated in functional assays measuring intrinsic activity at the human MT1 and MT2 receptors and demonstrated full agonism at both receptors. The chronobiotic properties of 2b were demonstrated in both acute and chronic rat models where 2b produced an acute phase advance of 32 min at 1 mg/kg and chronically entrained free-running rats with a mean effective dose of 0.23 mg/kg. Compound 2b is significantly less efficacious than melatonin in constricting human coronary artery. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.07.002
• 作为产物：
  描述：

  碘乙烷 、 2-溴-5-羟基苯甲酸甲酯 在 sodium hydride 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 4.0h， 生成 2-溴-5-乙氧基苯甲酸甲酯
  参考文献：
  名称：

  [EN] NOVEL COMPOUNDS
  [FR] NOUVEAUX COMPOSES

  摘要：

  本发明涉及新型苯丙氨酸化合物，其制备方法，包含它们的组合物以及它们在治疗或预防能够通过抑制细胞粘附而被调节的疾病中的应用。

  公开号：

  WO2005061440A1

文献信息

• Novel compounds
  申请人：Ward William Robert

  公开号：US20070043113A1

  公开（公告）日：2007-02-22

  The present invention relates to novel phenylalanine compounds, processes for their preparation, compositions comprising them and their use in the treatment or prevention of diseases capable of being modulated by the inhibition of cell adhesion.

  本发明涉及新型苯丙氨酸化合物，其制备方法，包含它们的组合物以及它们在治疗或预防通过细胞粘附抑制可调节的疾病中的使用。
• Singh, Journal Of Scientific and Industrial Research, 1952, vol. 11 B, p. 35
  作者：Singh

  DOI：——

  日期：——
• NOVEL COMPOUNDS
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP1701933B1

  公开（公告）日：2008-09-03
• Chronobiotic activity of N-[2-(2,7-dimethoxyfluoren-9-yl)ethyl]-propanamide. Synthesis and melatonergic pharmacology of fluoren-9-ylethyl amides
  作者：James R. Epperson、Marc A. Bruce、John D. Catt、Jeffrey A. Deskus、Donald B. Hodges、George N. Karageorge、Daniel J. Keavy、Cathy D. Mahle、Ronald J. Mattson、Astrid A. Ortiz、Michael F. Parker、Katherine S. Takaki、Brett T. Watson、Joseph P.Yevich

  DOI：10.1016/j.bmc.2004.07.002

  日期：2004.9

  A series of fluoren-9-yl ethyl amides (2) were synthesized and evaluated for human melatonin MT1 and MT2 receptor binding. N-[2-(2,7-dimethoxyfluoren-9-yl)ethyl]propanamide (2b) was selected and evaluated in functional assays measuring intrinsic activity at the human MT1 and MT2 receptors and demonstrated full agonism at both receptors. The chronobiotic properties of 2b were demonstrated in both acute and chronic rat models where 2b produced an acute phase advance of 32 min at 1 mg/kg and chronically entrained free-running rats with a mean effective dose of 0.23 mg/kg. Compound 2b is significantly less efficacious than melatonin in constricting human coronary artery. (C) 2004 Elsevier Ltd. All rights reserved.
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
  申请人：TANABE SEIYAKU CO

  公开号：WO2005061440A1

  公开（公告）日：2005-07-07

  The present invention relates to novel phenylalanine compounds, processes for their preparation, compositions comprising them and their use in the treatment or prevention of diseases capable of being modulated by the inhibition of cell adhesion.

  本发明涉及新型苯丙氨酸化合物，其制备方法，包含它们的组合物以及它们在治疗或预防能够通过抑制细胞粘附而被调节的疾病中的应用。